Interleukin-2 for Refractory Chronic Spontaneous Urticaria

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Chronic Spontaneous Uriticaria
Interventions
DRUG

Placebo intramuscular injection

On the basis of background treatment, intramuscular injection of placebo was added.

DRUG

Human interleukin-2 (I) intramuscular injection

On the basis of background treatment, intramuscular injection of human interleukin-2 (I) will be added.

Trial Locations (1)

410000

RECRUITING

the Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

West China Hospital

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Second Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

The First People's Hospital of Changde City

OTHER

collaborator

The Third People's Hospital of Hangzhou

OTHER

lead

Second Xiangya Hospital of Central South University

OTHER